Support Groups

Esketamine Receives Breakthrough Designation from F.D.A. for Major Depressive Disorder with Imminent Risk for Suicide.

FDA action marks second Breakthrough Therapy Designation for intranasal esketamine, highlighting its potential as treatment for patients with major depressive disorder who are at imminent risk for suicide and for those with treatment-resistant depression

http://www.jnj.com/news/all/Esketamine-Receives-Breakthrough-Therapy-Designation-from-US-Food-and-Drug-Administration-for-Major-Depressive-Disorder-with-Imminent-Risk-for-Suicide



(Visited 46 times, 1 visits today)

%d bloggers like this: